Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Intracoronary Infusion of Bone Marrow Mononuclear Cells in Patients With Previous Myocardial Infarction.

Phase II Clinical Trial on the Effect of Intracoronary Infusion of Bone Marrow Mononuclear Cells on Functional Recovery in Patients With Myocardial Chronic Back and Severely Depressed Left Ventricular Function.

Phase II clinical trial which will include all patients diagnosed with chronic anterior myocardial infarction (more than 6 months from the acute phase and the complete revascularization in which it is assessed the evolution of left ventricular function in patients to the monitoring against their own basal condition.

Included patients will be studied in the following conditions:

  • Basal condition: defined as the immediately preceding to the administration of cell therapy treatment.
  • Monitoring Condition 1: three months after drug administration of cell therapy. Includes non-invasive methods of exploration of ventricular function.
  • Monitoring Condition 2: six months after administration of treatment. Includes the same methods of exploration of ventricular function practised in the basal condition, including cardiac catheterism as well as non invasive methods.
  • Monitoring Condition 3: twelve months after administration of the cell therapy drug. Includes non-invasive methods of exploration of ventricular function.

The trial hypothesis we propose consists of mononuclear cells of bone marrow providing progenitor cells with regenerative capacity and also secreting several angiogenic factors, and their implantation into ischemic tissues should contribute with both elements to the angiogenesis and tissue regeneration with myocardial functional recovery

Studieöversikt

Status

Avslutad

Intervention / Behandling

Detaljerad beskrivning

This is an uncontrolled study in which the efficacy of the cell therapy drug is measured by comparing the variables of ventricular function after treatment to the basal condition prior to its application

The total number of patients to be studied 20. The study population will correspond to male and female patients with chronic anterior myocardial infarction (more than 6 months after the acute episode) and ventricular dysfunction. It is expected 36 months of inclusion and one year follow up

Patients will receive in a concomitant way the drug treatment established by the good practice, so it would certainly be possible that some improvement occurs due to drug treatment.

It will be studied the patient population of both genders aged between 18 and 80 years diagnosed with Chronic anterior myocardial infarction (more than 6 months after the acute phase and the complete revascularization).

Objectives of the study:

  • Main objective: To determine the efficacy of intracoronary injection of adult stem cells from autologous bone marrow in patients with chronic anterior myocardial infarction in terms of improvement of ventricular function, determined by hemodynamic, echocardiographic and New York Heart Association (NYHA) functional class criteria, resulting in an improvement of heart failure symptoms and quality of life's patient.
  • Secondary objectives:

    1. To investigate the basic cellular mechanisms underlying the myocardial regeneration process through correlation between hemodynamic criteria for the ventricular function improvement and the biologicals corresponding to the composition and the functionality of the infused cells.
    2. To analyze clinical, hemodynamic and biologicals factors able to influence favorably to a greater degree of functional recovery after regenerative treatment in chronic myocardial infarction.
    3. To design, in view of the results obtained, suitable protocol for the application of cell therapy to treat patients with old anterior infarction, both in terms of the ideal characteristics of medullary graft as in terms of those patients more likely to be beneficiaries of it, in order to establish a definitive strategy of including cell therapy in the standard treatment of this disease in the near future provided that the results indicate it so.

The primary variable is the improvement in ventricular function monitoring under angiographic and echocardiographic parameters.

Studietyp

Interventionell

Inskrivning (Faktisk)

20

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Cordoba, Spanien, 14004
        • University Hospital Reina Sofía

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Aged between 18 and 80 years.
  2. Patients diagnosed with Chronic anterior myocardial infarction (more than 6 months from the acute episode) with symptoms and / or signs of heart failure.
  3. Left ventricular ejection fraction (LVEF)<45% and distensibility changes.
  4. Complete revascularization performed at least 6 months before infusion cells.

Exclusion Criteria:

  1. Patients in active waiting list for heart transplantation..
  2. Treatable patients with resynchronization.
  3. Patients over 80 years
  4. Coexistence of other serious systemic diseases.
  5. Active infection, HIV, Hepatitis B or Hepatitis C.
  6. Patients with malignant or pre-malignant tumours.
  7. Coexistence of any haematological disease.
  8. Pregnant women, in breastfeeding period, or in childbearing potential age who are not using effective contraception.
  9. Patients who are currently participating or have completed their participation in a clinical trial in a period of less than three months.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Intervention
Dose of bone marrow mononuclear cells: 5-7 x 108 total cells
Intracoronary infusion of autologous bone marrow-derived mononuclear cells

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Change from baseline in left ventricular ejection fraction (LVEF)
Tidsram: 3, 6 and 12 months after intervention
3, 6 and 12 months after intervention

Sekundära resultatmått

Resultatmått
Tidsram
Major Adverse Cardiac Events (MACE)
Tidsram: 12 months
12 months
Functional grade of the New York Heart Association (NYHA)
Tidsram: 3,6 and 12 months
3,6 and 12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studiestol: Inmaculada Herrera, MD, PhD, University Hospital Reina Sofía, Córdoba.
  • Studiestol: Jose Suarez de lezo, MD, PhD, University Hospital Reina Sofía, Córdoba.
  • Huvudutredare: Miguel Ángel Romero, MD, University Hospital Reina Sofía, Córdoba.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 december 2010

Primärt slutförande (Faktisk)

1 februari 2015

Avslutad studie (Faktisk)

1 februari 2015

Studieregistreringsdatum

Först inskickad

12 oktober 2011

Först inskickad som uppfyllde QC-kriterierna

18 oktober 2011

Första postat (Uppskatta)

19 oktober 2011

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

30 juni 2015

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 juni 2015

Senast verifierad

1 november 2014

Mer information

Termer relaterade till denna studie

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera